Serum Prolactin in Pregnancy Predicts Prediabetes/Diabetes

This article originally appeared here.
Share this content:
Serum Prolactin in Pregnancy Predicts Prediabetes/Diabetes
Serum Prolactin in Pregnancy Predicts Prediabetes/Diabetes

MONDAY, May 2, 2016 (HealthDay News) -- Serum prolactin in pregnancy predicts the risk of postpartum prediabetes/diabetes, according to a study published online April 26 in Diabetes Care.

Ravi Retnakaran, M.D., from Mount Sinai Hospital in Canada, and colleagues measured fasting serum prolactin, human placental lactogen (HPL), and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) in 367 women in the late second/early third trimester. Participants underwent an oral glucose tolerance test (OGTT) at three months postpartum.

The researchers identified 301 women with normal glucose tolerance (NGT) in the postpartum OGTT and 66 with prediabetes or diabetes. Women with postpartum NGT had higher serum prolactin in pregnancy than those with postpartum prediabetes/diabetes; no differences were seen for HPL and CMPF between the groups. Antepartum prolactin was an independent determinant of postpartum, insulin secretion-sensitivity index-2 on multiple linear regression analyses. Independent prediction of a reduced risk of postpartum prediabetes/diabetes was possible with higher serum prolactin (odds ratio, 0.5).

"Higher prolactin in pregnancy is an independent predictor of both better β-cell function and a lower likelihood of prediabetes/ diabetes after complete adjustment for type 2 diabetes risk factors," the authors write. "It thus emerges that serum prolactin in pregnancy is a previously unrecognized factor that can provide novel insight into postpartum diabetes risk in young women."

Retnakaran is part holder of a patent for CMPF as a biomarker for diabetes.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

FDA OKs Doptelet for Liver Dz Patients Undergoing ...

Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure

Slower Decline in Lung Function With Anthocyanin Intake

Slower Decline in Lung Function With Anthocyanin Intake

Slower annual rates of decline in FEV1 and FVC for those in highest quartile of anthocyanin intake

Bioengineering Feasible for Airway Reconstruction

Bioengineering Feasible for Airway Reconstruction

Bioengineered tracheal and bronchial reconstruction reported using stented aortic matrices

is free, fast, and customized just for you!

Already a member?

Sign In Now »